4.0 Article

Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau

期刊

BRAIN COMMUNICATIONS
卷 2, 期 1, 页码 -

出版社

OXFORD UNIV PRESS
DOI: 10.1093/braincomms/fcaa025

关键词

tau; verbal memory; sex differences; Alzheimer's disease

资金

  1. Shiley-Marcos Alzheimer's Disease Research Center [P30 AG062429]
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  3. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. Bristol-Myers Squibb Company
  13. CereSpir, Inc.
  14. Cogstate
  15. Eisai, Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.
  20. Fujirebio
  21. GE Healthcare
  22. IXICO Ltd.
  23. Janssen Alzheimer Immunotherapy Research & Development, LLC
  24. Johnson & Johnson Pharmaceutical Research & Development LLC
  25. Lumosity
  26. Lundbeck
  27. Merck Co., Inc.
  28. Meso Scale Diagnostics, LLC
  29. NeuroRx Research
  30. Neurotrack Technologies
  31. Novartis Pharmaceuticals Corporation
  32. Pfizer, Inc.
  33. Piramal Imaging
  34. Servier
  35. Takeda Pharmaceutical Company
  36. Transition Therapeutics
  37. Canadian Institutes of Health Research
  38. NIA/NIH [U01 AG016976]
  39. NIA [P30 AG019610, P30 AG013846, P30 AG062428-01, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P30 AG062421-01, P30 AG062422-01, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50 AG047366, P30 AG010129]
  40. [P50 AG016573]
  41. [P30 AG062429-01]
  42. [P50 AG023501]
  43. [P30 AG035982]
  44. [P30 AG028383]
  45. [P30 AG053760]
  46. [P30 AG010124]
  47. [P50 AG005133]
  48. [P50 AG005142]
  49. [P30 AG012300]
  50. [P30 AG049638]
  51. [P50 AG005136]
  52. [P30 AG062715-01]
  53. [P50 AG005681]
  54. [P50 AG047270]

向作者/读者索取更多资源

In this study, we aimed to assess whether women are able to withstand more tau before exhibiting verbal memory impairment. Using data from 121 amyloid-beta-positive Alzheimer's Disease Neuroimaging Initiative participants, we fit a linear model with Rey Auditory Verbal Learning Test score as the response variable and tau-PET standard uptake value ratio as the predictor and took the residuals as an estimate of verbal memory reserve for each subject. Women demonstrated higher reserve (i.e. residuals), whether the Learning (t = 2.78, P = 0.006) or Delay (t = 2.14, P = 0.03) score from the Rey Auditory Verbal Learning Test was used as a measure of verbal memory ability. To validate these findings, we examined 662 National Alzheimer's Coordinating Center participants with a C2/C3 score (Consortium to Establish a Registry for Alzheimer's Disease) at autopsy. We stratified our National Alzheimer's Coordinating Center sample into Braak 1/2, Braak 3/4 and Braak 5/6 subgroups. Within each subgroup, we compared Logical Memory scores between men and women. Men had worse verbal memory scores within the Braak 1/2 (Logical Memory Immediate: beta = -5.960 +/- 1.517, P< 0.001, Logical Memory Delay: beta = -5.70361.677, P = 0.002) and Braak 3/4 (Logical Memory Immediate: beta = -2.90060.938, P = 0.002, Logical Memory Delay: beta = -2.672 +/- 0.955, P = 0.006) subgroups. There were no sex differences in Logical Memory performance within the Braak 5/6 subgroup (Logical Memory Immediate: beta = -0.314 +/- 0.328, P = 0.34, Logical Memory Delay: beta = -0.195 +/- 0.287, P = 0.50). Taken together, our results point to a sex-related verbal memory reserve.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据